The Analyst Verdict: CARISMA Therapeutics In The Eyes Of 4 Experts
Portfolio Pulse from Benzinga Insights
In the past three months, four analysts have provided ratings for CARISMA Therapeutics (NASDAQ:CARM), all of which are bullish. The average 12-month price target has dropped by 22.5% to $7.75. Key analysts have maintained or lowered their buy ratings, reflecting dynamic market conditions and company performance.
May 17, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CARISMA Therapeutics has received four bullish ratings from analysts over the past three months. The average 12-month price target has decreased by 22.5% to $7.75, with a high estimate of $9.00 and a low estimate of $6.00. Analysts have maintained or lowered their buy ratings, reflecting recent market conditions and company performance.
The consistent bullish ratings from analysts suggest positive sentiment towards CARISMA Therapeutics. However, the significant drop in the average price target indicates tempered expectations for future performance. The maintained or lowered buy ratings reflect cautious optimism amid dynamic market conditions.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100